Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Accured Expenses: 2010-2024

Historic Change in Accured Expenses for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $1.1 million.

  • OptimizeRx's Change in Accured Expenses fell 93333.33% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 21729.55%. This contributed to the annual value of $1.1 million for FY2024, which is 1918.65% down from last year.
  • Per OptimizeRx's latest filing, its Change in Accured Expenses stood at $1.1 million for FY2024, which was down 1918.65% from $1.3 million recorded in FY2023.
  • OptimizeRx's 5-year Change in Accured Expenses high stood at $1.4 million for FY2020, and its period low was -$301366.0 during FY2022.
  • In the last 5 years, OptimizeRx's Change in Accured Expenses had a median value of $1.1 million in 2024 and averaged $790798.6.
  • As far as peak fluctuations go, OptimizeRx's Change in Accured Expenses tumbled by 16246.25% in 2022, and later skyrocketed by 53236.46% in 2023.
  • Annual analysis of 5 years shows OptimizeRx's Change in Accured Expenses stood at $1.4 million in 2020, then tumbled by 65.95% to $482475.0 in 2021, then tumbled by 162.46% to -$301366.0 in 2022, then surged by 532.36% to $1.3 million in 2023, then dropped by 19.19% to $1.1 million in 2024.
  • Its Change in Accured Expenses was $1.1 million in FY2024, compared to $1.3 million in FY2023 and -$301366.0 in FY2022.